摘要
目的观察丹奥和低分子肝素联合治疗进展性脑梗死的疗效及安全性。方法80例急性进展性脑梗死患者随机分为治疗组和对照组,每组40例。治疗组予丹奥及克赛。对照组应用丹奥。在给药前、给药后14d,检测血小板聚集率和凝血4项。对2组患者进行神经功能缺失评分。结果用药14d后,治疗组活化部分凝血活酶时间(APTT)较治疗前升高(P<0.05),对照组则无显著性差异(P>0.05)。治疗组总有效率为89.7%,优于对照组的77.5%。用药14d后,治疗组神经功能缺失评分较对照组改善(P<0.05)。结论丹奥和克赛联合治疗进展性脑梗死临床疗效更佳。
Objective To observe the combined effect and safety of Sodium Ozagrel and Low Molecular Heparin in the treatment of progressive cerebral infraction. Methods 80 patients with progressive cerebral infraction were divided into experiment group and control group with 40 patients in each group. Sodium Ozagrel and Clexane both were used in the experimental group, but only Sodium Ozagrel was used in the control group. Platelet packing fraction and 4 items of blood clotting were examined before and 14 d after treatment. Neurofunetional defect was evaluated at the same time in the 2 groups. Results Platelet packing fractions were significantly different when examined before treatment and 14 d after treatment both in 2 groups （P 〈 0.05）, but no difference between the 2 groups. The value of APTT 14 d after treatment in the experimental group was significantly increased （P 〈 0.05）, while this was not observed in the control group. Total effective power in experimental group was 89.7%, which was much higher than that in control group （77.5%）. Neurofunctional defect evaluation in experimental group was significantly improved after treatment （P 〈 0.05） compared with that in control. Conclusion Sodium Ozagrel combined with Clexane is more effective on progressive cerebral infraction.
出处
《中国康复理论与实践》
CSCD
2006年第5期410-411,共2页
Chinese Journal of Rehabilitation Theory and Practice
关键词
丹奥
低分子肝素
进展性脑梗死
Sodium Ozagrel
Low Molecular Heparin
progressive cerebral infraction
作者简介
高乐虹（1973-）,女,北京市人,硕士研究生,医师,主要从事神经电生理的研究.
